SAMMPRIS试验中颅内动脉支架置入后非手术期症状性梗死与支架内再狭窄
本研究基于SAMMPRIS试验,分析颅内动脉支架置入后非手术期症状性支架内再狭窄(ISR)的发生率及其对非手术期症状性梗死的贡献。183例无围手术期主要终点的支架组患者中,随访中位35.0个月,27例(14.8%)发生症状性梗死,其中17例(9.3%)为缺血性卒中,10例(5.5%)为伴暂时性体征的脑梗死;症状性ISR的1年、2年、3年发生率分别为9.6%、11.3%、14.0%。结论认为症状性ISR在3年随访中至少见于1/7的患者,且可能导致了多数非手术期脑梗死。
要点
- 支架组无围手术期终点患者中,14.8%发生症状性梗死,9.3%为缺血性卒中。
- 症状性ISR的3年累积发生率为14.0%(95%CI 9.6%-20.2%)。
- 发生梗死且可行血管成像者中,66.7%显示支架内再狭窄。
核心结论
- 症状性ISR在SAMMPRIS支架队列3年随访中至少见于1/7的患者,且可能导致了多数非手术期脑梗死。
研究设计与样本
- SAMMPRIS试验支架组中无围手术期主要终点的183例患者,随访中位35.0个月,评估症状性ISR及非手术期症状性梗死。
主要发现
- 27例(14.8%)发生症状性梗死,其中17例(9.3%)为缺血性卒中,10例(5.5%)为伴暂时性体征的脑梗死。
- 16例(8.7%)发生短暂性脑缺血发作(TIA)。
- 24例梗死患者有足够血管成像,其中16例(66.7%)显示ISR;10例TIA患者中8例(80%)显示ISR。
- 症状性ISR的1年、2年、3年发生率分别为9.6%(95%CI 6.1%-14.9%)、11.3%(95%CI 7.5%-17.0%)、14.0%(95%CI 9.6%-20.2%)。
临床怎么用
- 颅内动脉支架置入后应长期监测支架内再狭窄,尤其对发生缺血性事件的患者进行血管成像评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The purpose of this study was to investigate the frequency of symptomatic in-stent restenosis (ISR) and its contribution to nonprocedural symptomatic infarction in the SAMMPRIS trial (Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis). METHODS: Patients without a periprocedural primary end point were followed up to determine the occurrence of any of the following events: ischemic stroke, cerebral infarct with temporary signs, or transient ischemic attack in the territory of the stented artery. Vascular imaging performed after these events was reviewed for ISR. Annual rates for symptomatic ISR were calculated using Kaplan-Meier estimates. RESULTS: Of 183 patients in the stenting group without a periprocedural primary end point, 27 (14.8%) had a symptomatic infarction (stroke or cerebral infarct with temporary signs) and 16 (8.7%) had transient ischemic attack alone in the territory during a median follow-up of 35.0 months. Of the 27 patients with infarctions, 17 (9.3%) had an ischemic stroke and 10 (5.5%) had a cerebral infarct with temporary signs alone. Adequate vascular imaging to evaluate ISR was available in 24 patients with infarctions (showing ISR in 16 [66.7%]) and in 10 patients with transient ischemic attack alone (showing ISR in 8 [80%]). The 1-, 2-, and 3-year rates (with 95% confidence limits) for symptomatic ISR in the SAMMPRIS stent cohort were 9.6% (6.1%-14.9%), 11.3% (7.5%-17.0%), and 14.0% (9.6%-20.2%), respectively. CONCLUSIONS: Symptomatic ISR occurred in at least 1 of 7 patients in SAMMPRIS by 3 years of follow-up and was likely responsible for the majority of nonprocedural cerebral infarctions. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT00576693.
引用
- Derdeyn CP, Fiorella D, Lynn MJ, et al. Nonprocedural Symptomatic Infarction and In-Stent Restenosis After Intracranial Angioplasty and Stenting in the SAMMPRIS Trial (Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis). Stroke. 2017. PMID: 28455321. doi:10.1161/STROKEAHA.116.014537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。